Shots: The approval is based on P-III KEYNOTE-426 study assessing Keytruda (pembrolizumab, 200mg, q3w up to 24mos.) + Inlyta (axitinib,5mg, bid) vs sunitinib (50mg, qd for 4wks.) in 861 patients […]Read More
Tags : RCC
Shots: The P-III TIVO-3 study involves assessing of Fotivda (tivozanib) vs sorafenib in 350 patients with refractory advanced or metastatic renal cell carcinoma (RCC) P-III TIVO-3 results: 44% improvement in […]Read More
Shots: The P-III JAVELIN Renal 101 trial involves assessing of Bavencio (avelumab) + Inlyta (axitinib) vs Sutent (sunitinib) in 886 patients with previously untreated advanced RCC P-III JAVELIN Renal 101 […]Read More
Shots: The P-III CheckMate-214 study involves assessing of Opdivo (nivolumab, 3mg/kg) + Yervoy (ipilimumab,1mg/kg) vs sunitinib (50mg qd @4wks.) in patients with previously untreated advanced or metastatic renal cell carcinoma […]Read More
Shots: The approval is based on P-III CheckMate-214 study results assessing Opdivo (3mg/kg) + low-dose Yervoy(1mg/kg) vs sunitinib (50mg, qd) in patients with previously untreated advance RCC P-III Checkmate-214 study […]Read More
Shots: CHMP recommendation is based on the results of P-III CheckMate-214 study assessing Opdivo 3 mg/kg (q3w @four doses, q2w) + Yervoy 1 mg/kg vs sunitinib (50 mg qd @four […]Read More
Latest Posts
